Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | PHASE3 | RECRUITING | 510 | — | — | Jun 1, 2026 | Feb 1, 2029 | Jun 8, 2026 | 13 | United States, Australia |
The OS of participants with atebimetinib in combination with mGnP versus GnP
| Arm | Type | Description |
|---|---|---|
| Atebimetinib + mGnP | EXPERIMENTAL | Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| GnP | ACTIVE_COMPARATOR | Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| Name | Type | Description |
|---|---|---|
| Atebimetinib | DRUG | Once daily oral tablets |
| GnP | DRUG | Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion |
| mGnP | DRUG | Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel) |
Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma at least 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatme...